Avalo Therapeutics: Phase-2 Success and Fresh Capital Fuel Biotech Hope - BofA Recommends Buy with Target of $35!
Reading Time: 3 minutes
Focus on Unmet Medical Needs Avalo Therapeutics (AVTX) presents itself in the current biotech landscape as an exciting company that is fully focused on the treatment of immune-mediated inflammatory diseases. As a so-called "clinical-stage" biotech company, Avalo is currently not generating any revenue. The business model is typical for emerging players in the industry: the research and development of innovative therapies up to the point of regulatory approval. This capital-intensive path is financed through the stock market in order to achieve...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
